

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Hansoh Pharmaceutical Group Company Limited**

**翰森製藥集團有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 3692)**

### **DATE OF BOARD MEETING**

The board of directors (the “**Board**”) of Hansoh Pharmaceutical Group Company Limited (the “**Company**”) hereby announces that a meeting of the Board of the Company will be held on Monday, August 18, 2025 for the purpose of, among other things, considering and approving the interim results of the Company and its subsidiaries for the six months ended June 30, 2025, recommendation of an interim dividend, if any, and transacting any other business.

By Order of the Board  
**Hansoh Pharmaceutical Group Company Limited**  
**Zhong Huijuan**  
*Chairlady*

Hong Kong, August 6, 2025

*As at the date of this announcement, the Board comprises Ms. Zhong Huijuan as chairlady and executive director, Ms. Sun Yuan and Dr. Lyu Aifeng as executive directors, and Mr. Lin Guoqiang, Mr. Chan Charles Sheung Wai and Ms. Yang Dongtao as independent non-executive directors.*